Charles River Laboratories International, Inc. (CRL) Compounding Analysis | TGMCharts
Charles River Laboratories International, Inc. (CRL) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
Score
27/100
10Y CAGR
11.4%
Median YoY
10.8%
YoY volatility
σ 10.7pp· uneven
Quarters ≥ 20%
10 of 40
Negative quarters
9
Valuation vs own 10Y history
P/S 3.5x · 10Y median 2.8x · 82nd percentile · as of Aug 19, 2026
How this score is computed
Quarters at or above 20%: 10 of 40 → 10 of 40 pts
Steadiness (typical swing 10.7pp) → 17.4 of 25 pts
Pace (median 10.8% YoY) → 0 of 20 pts
Latest quarter (-2.7% YoY) → 0 of 15 pts
Score: 27 of 100
Annualized revenue (TTM) · by quarter, last 40
tgmcharts.com
Quarterly YoY revenue growth vs the 20% line
tgmcharts.com
P/S multiple vs its 10Y median
tgmcharts.com
Across metrics · 10Y
CRL reported stats per metric over 10Y: annual CAGR, median quarterly year-over-year growth, YoY standard deviation, quarters at or above 20%, and negative quarters.
Metric
10Y CAGR
Median YoY
YoY σ
Qtrs ≥ 20%
Neg. qtrs
RevenueRevenue
11.4%
10.8%
10.7pp
10 of 40
9
EPSEPS
—
11%
29.0pp
12 of 37
16
Op cash flowOperating cash flow
9.9%
7.8%
69.0pp
14 of 40
16
EBITDAEBITDA
11.7%
10.4%
17.3pp
11 of 38
11
FCFFree cash flow
8.8%
9.9%
320.8pp
16 of 37
15
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →